Venous Thromboembolism in Cancer: Frequently Asked Questions When Guidelines are Inconclusive

Palla, Antonio; Celi, Alessandro; Marconi, Letizia; Pistelli, Francesco; Tavanti, Laura; Desideri, M; Carrozzi, Laura

doi:10.3109/07357907.2015.1009631

Cited by 5 publications

(3 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has been possible because a center for the diagnosis and treatment of PE is active at the University Hospital, where patients are followed according to a standard clinical strategy. [31] Other authors reported results on patients followed for years after the discontinuation of 3 to 6 months of prophylaxis [3,8,27,30] or treated for a longer period of time but following a nonstandardized protocol. [30] Recently, a standardized, prospective study reported results on patients with unprovoked PE systematically treated for 18 months.…”

Section: Discussionmentioning

confidence: 99%

Five-year follow-up of pulmonary embolism under anticoaugulation

et al. 2016

View full text Add to dashboard Cite

Benefits and harms of long-term anticoagulant therapy (AT) after acute pulmonary embolism (PE) are poorly known. The aim of this study was to investigate the outcome of patients with PE treated with AT for 5 years according to American College of Chest Physicians (ACCP) guidelines.Patients with both unprovoked and secondary PE were consecutively enrolled in a “real life” study. After a 12-month AT, they continued or stopped the treatment according to ACCP guidelines, and were followed-up for 5 years. Outcomes were all-cause mortality, recurrence, and fatal recurrence under AT.Of the original consecutive 585 patients, 471 were included (83 dead, 31 lost during the 1st year). Of these, 361 (76.6%) continued AT. During 5 years, death occurred in 109 (30.2%) patients, with a mortality rate of 8.00 events/100 person-years of follow-up; recurrence in 34 (9.4%), with an incidence rate of 2.58 events/person-years; fatal recurrence in 13 (3.6%), with an incidence rate of 0.95 events/person-years. The case fatality rate for recurrence was 38.2%. In the subgroup of patients with unprovoked PE, the chance of dying was significantly lower (RR 0.35; 95% confidence interval 0.24–0.53) and the tendency to fatal recurrence (not significantly) greater (0.11 events/100 person-years vs 0.07 events/100 person-years) than in the remaining patients. Major bleeding occurred in 5 (1.3%) patients. The case fatality rate for bleeding was 14.3%.During 5-year AT, 30% of patients dies, 10% experiences recurrences, and 5% has fatal recurrences. According to guidelines, most patients need to continue AT; the case fatality rate for bleeding is lower than that for recurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Five-year follow-up of pulmonary embolism under anticoaugulation

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The difference did not reach statistical significance; furthermore, the number of cancer related deaths was very small (8/199 in the control group and 4/197 in the screening group); these data, together with the physical and emotional discomfort for the patients related to the very demanding screening program, and with the cost of the program, suggest that extensive screening for cancer is not routinely warranted in patients with VTE. An approach based on individual characteristics that emerge after the initial history, physical examination, routine blood tests, and chest X-ray is for example what we recommend in patients admitted to our ward (22).…”

Section: Screening For Occult Cancer After An Episode Of Vtementioning

confidence: 99%

Cancer-associated venous thromboembolism

2022

Nat Rev Dis Primers

View full text Add to dashboard Cite

“…Because of the dependency of tumor growth to thrombosis, coagulation factors could be considered as a major risk factor in tumorigenesis [3,4]. Several studies have investigated the role of thrombosis factors in tumors and have shown the importance of thrombosis management in tumor treatment [5,6]. Although the coincidence of myoma and thrombosis is reported in several types of research [7,8], published studies on the association between myoma and thrombosisrelated mutations are limited.…”

Section: Introductionmentioning

confidence: 99%

Thrombosis-Related Factors FV and F13A1 Mutations in Uterine Myomas

Ahmadi

Nasiri

Ebrahimi

2016

Zahedan J Res Med Sci

View full text Add to dashboard Cite

Background: Uterine myoma is a common benign, solid tumor in women with reproductive age. Thrombosis factors play a major role in tumor formation and also tumors induce thrombotic processes. Factor V (FV) and factor 13A1 (F13A1) are two thrombotic factors, which their dysfunctions affect the clot formation. FV Leiden, a common mutation in F5 gene, and V34L mutation in F13A1 gene are known to affect the risk of thrombosis. The purpose of the present study was to determine the possible association of FV Leiden and F13A1 Valine to Leucine at codon 34 (Val34Leu) mutations with the risk of developing uterine myoma in the women from south of Iran. Methods: In this case-control study, FV Leiden and V34L mutations were genotyped in 73 myoma patients and 73 healthy subjects using amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). The data were analyzed by logistic regression,

show abstract

Venous Thromboembolism in Cancer: Frequently Asked Questions When Guidelines are Inconclusive

Cited by 5 publications

References 125 publications

Five-year follow-up of pulmonary embolism under anticoaugulation

Five-year follow-up of pulmonary embolism under anticoaugulation

Cancer-associated venous thromboembolism

Thrombosis-Related Factors FV and F13A1 Mutations in Uterine Myomas

Contact Info

Product

Resources

About